Interaction of chloropromazine with adrenochrome and interference of a possible endogenous psychotogenic agent with some synaptic enzyme activities.
D000323:Adrenochrome / Q000494:pharmacology*; D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology; D001921:Brain / Q000201:enzymology; D002110:Caffeine / Q000494:pharmacology; D002746:Chlorpromazine / Q000008:administration & dosage / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors; D002845:Chromatography; D000242:Cyclic AMP / Q000494:pharmacology; D004347:Drug Interactions; D006213:Hallucinogens / Q000494:pharmacology*; D000882:Haplorhini; D008094:Lithium / Q000494:pharmacology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010101:Oxygen Consumption / Q000187:drug effects; D010215:Papio; D013053:Spectrophotometry; D013569:Synapses / Q000187:drug effects / Q000201:enzymology*; D013574:Synaptosomes / Q000187:drug effects / Q000201:enzymology
D002800:Cholinesterase Inhibitors; D006213:Hallucinogens; D008996:Monoamine Oxidase Inhibitors; D002110:Caffeine; D000323:Adrenochrome; D008094:Lithium; D000242:Cyclic AMP; D001205:Ascorbic Acid; D002746:Chlorpromazine